Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard Parnes

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
The New England Journal of Medicine|July 5, 2023
Screening for Prostate Cancer. ReplyPaul F Pinsky, Howard Parnes
The New England Journal of Medicine|April 12, 2023
Screening for Prostate CancerPaul F Pinsky, Howard Parnes
Cancer Prevention Research (Philadelphia, Pa.)|January 14, 2009
Estimating rates of true high-grade disease in the prostate cancer prevention trialPaul Pinsky, Howard Parnes, Leslie Ford
Oncology (Williston Park, N.Y.)|September 12, 2003
Clinical trials referral resource. Current NCI-sponsored clinical trials in prostate cancer: prevention, treatment, supportive care, and imagingAlison Martin, Ronald Lieberman, Howard Parnes, et al.
Preventive Medicine|August 27, 2021
Adherence with protocol medication use and mortality from unrelated causes in a prevention trialPaul Pinsky, Phyllis Goodman, Howard Parnes, et al.
The Journal of Urology|December 22, 2020
Other and All-Cause Mortality among Men Diagnosed with Prostate Cancer in the PLCO TrialDudith Pierre-Victor, Paul F Pinsky, Eric Miller, et al.
Cancer|August 16, 2012
Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trialsPaul F Pinsky, Amanda Black, Robert Grubb, et al.
The Journal of Urology|July 4, 2006
Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancerEdward Messing, Kyung Mann Kim, Francis Sharkey, et al.
Pharmacotherapy|March 12, 2003
Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancerMcDonald K Horne, William D Figg, Phil Arlen, et al.
Oncotarget|January 6, 2017
Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechinsNagi B Kumar, Julio Pow-Sang, Philippe E Spiess, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
The New England Journal of Medicine|July 5, 2023
Screening for Prostate Cancer. ReplyPaul F Pinsky, Howard Parnes
The New England Journal of Medicine|April 12, 2023
Screening for Prostate CancerPaul F Pinsky, Howard Parnes
Cancer Prevention Research (Philadelphia, Pa.)|January 14, 2009
Estimating rates of true high-grade disease in the prostate cancer prevention trialPaul Pinsky, Howard Parnes, Leslie Ford
Oncology (Williston Park, N.Y.)|September 12, 2003
Clinical trials referral resource. Current NCI-sponsored clinical trials in prostate cancer: prevention, treatment, supportive care, and imagingAlison Martin, Ronald Lieberman, Howard Parnes, et al.
Preventive Medicine|August 27, 2021
Adherence with protocol medication use and mortality from unrelated causes in a prevention trialPaul Pinsky, Phyllis Goodman, Howard Parnes, et al.
The Journal of Urology|December 22, 2020
Other and All-Cause Mortality among Men Diagnosed with Prostate Cancer in the PLCO TrialDudith Pierre-Victor, Paul F Pinsky, Eric Miller, et al.
Cancer|August 16, 2012
Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trialsPaul F Pinsky, Amanda Black, Robert Grubb, et al.
The Journal of Urology|July 4, 2006
Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancerEdward Messing, Kyung Mann Kim, Francis Sharkey, et al.
Pharmacotherapy|March 12, 2003
Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancerMcDonald K Horne, William D Figg, Phil Arlen, et al.
Oncotarget|January 6, 2017
Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechinsNagi B Kumar, Julio Pow-Sang, Philippe E Spiess, et al.
Pageof 4